Artelo Biosciences Announces FABP5 Inhibitor Study Demonstrating Anxiety and Depression Reductions in Preclinical Models.

Artelo Biosciences published a peer-reviewed study demonstrating that intraperitoneal administration of a novel FABP5 inhibitor significantly reduces stress-induced anxiety and depression behaviors in preclinical models. The study validates FABP5 inhibition and strengthens the therapeutic potential of Artelo's FABP5 platform for mood and stress-related disorders. Key findings include reduced anxiety and depression-like behaviors, increased gene expression of key receptors in the endocannabinoid system, and prevention of stress-induced reductions in hippocampal neurogenesis.